KBC Group’s MBX Biosciences MBX Stock Holding History

KBC Group’s Portfolio MBX Stock Details MBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$45K	Hold	810	–	–	﹤0.01%	1742
2026 Q1	$24K	Buy	+810	New	+$27.5K	﹤0.01%	1829

Other funds holding MBX

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

NVP Associates Menlo Park, California $328M AUM 166.51% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

KBC Group's MBX Position: Q2 2026 in Review

KBC Group held its MBX Biosciences (MBX) position steady in Q2 2026 at 810 shares worth $45K. The position accounts for ﹤0.01% of the portfolio, ranked #1742.

KBC Group first reported a position in MBX in Q1 2026 and has held it in 2 quarters since. 172 funds tracked by Wall St. Rank hold MBX as of Q2 2026.

KBC Group held 810 shares of MBX Biosciences worth $45K as of Q2 2026.
KBC Group left its MBX Biosciences share count unchanged in Q2 2026.
MBX Biosciences made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #1742 holding.
KBC Group first reported a position in MBX Biosciences in Q1 2026 and has held it in 2 quarters since.
172 funds tracked by Wall St. Rank held MBX Biosciences as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.